Karim Fizazi
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
Overview
Karim Fizazi is Head of Medical Oncology at Gustave Roussy and Professor at Paris-Saclay, with links to Centre Oscar Lambret. His specialisms are prostate cancer, genitourinary oncology, hormone therapy and radioligand therapy. He is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE, the New England Journal of Medicine trial of abiraterone plus prednisone in high-risk metastatic castration-sensitive prostate cancer, and PEACE-1, the Lancet trial adding abiraterone to androgen deprivation therapy and docetaxel in de novo metastatic disease. He has also led studies of radium-223 and PSMA radioligands, and is linked to the ALSYMPCA trial. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE) | NEJM | 2017 |
| Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1) | Lancet | 2022 |
| VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer | New England Journal of Medicine | 2021 |
| ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer | New England Journal of Medicine | 2019 |
For men who still have a working hormone treatment option but whose cancer is progressing, offering the PSMA radioligand therapy sooner - before chemotherapy - delayed disease progression, though it did not clearly extend how long men lived once the very high rate of patients switching over is accounted for.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Similar pages
not linked directly; found by shared links- TermAndrogen receptor pathway inhibitor (ARPI)
Shares Radium-223 with abiraterone: a caution, not a combination, PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, Abiraterone acetate, Prostate cancer.
- PersonA. Oliver Sartor
Shares ALSYMPCA, PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Radium-223.
- CollectionProstate Cancer Foundation (PCF)
Shares Abiraterone acetate, Radium-223, Prostate cancer.
- PersonChris C. Parker
Shares Radium-223 with abiraterone: a caution, not a combination, Radium-223, Prostate cancer.
- TermBone metastases and skeletal-related events
Shares Radium-223 with abiraterone: a caution, not a combination, Radium-223 dichloride, Radium-223, Prostate cancer.
- IndicationBone pain palliation from osteoblastic metastases
Shares ALSYMPCA, Radium-223 dichloride, Radium-223.
- TermmCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)
Shares Abiraterone acetate, Radium-223, Prostate cancer.
- PersonMichael J. Morris
Shares PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Prostate cancer.